GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » FCF Margin %

NLS Pharmaceutics (NLS Pharmaceutics) FCF Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NLS Pharmaceutics's Free Cash Flow for the six months ended in Dec. 2023 was $-2.39 Mil. NLS Pharmaceutics's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, NLS Pharmaceutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, NLS Pharmaceutics's current FCF Yield % is -169.32%.

The historical rank and industry rank for NLS Pharmaceutics's FCF Margin % or its related term are showing as below:


NLSP's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -139.31
* Ranked among companies with meaningful FCF Margin % only.


NLS Pharmaceutics FCF Margin % Historical Data

The historical data trend for NLS Pharmaceutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics FCF Margin % Chart

NLS Pharmaceutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
Get a 7-Day Free Trial - - - - -

NLS Pharmaceutics Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NLS Pharmaceutics's FCF Margin %

For the Biotechnology subindustry, NLS Pharmaceutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NLS Pharmaceutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where NLS Pharmaceutics's FCF Margin % falls into.



NLS Pharmaceutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

NLS Pharmaceutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-9.684/0
= %

NLS Pharmaceutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-2.388/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NLS Pharmaceutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Traded in Other Exchanges
N/A
Address
The Circle 6, Zurich, CHE, 8058
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.